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ABSTRACT
Introduction: Evidence in the literature indicates that patients with type 2 diabetes (T2D) 
have a very low level of adherence to pharmacological treatment and that despite several 
interventions to improve it, a number of obstacles to optimal care limit the extent to which 
such goals can be achieved. This study attemts to assess the sociodemographic profile 
of patients with T2D, and to identify the main reasons for nonadherence.
Methods: This cross-sectional study evaluated patients with T2D for at least 6 months 
who are regularly followed at an endocrinology outpatient clinic or who have been 
admitted to a university hospital. Adherence was assessed by a modifed Morisky 
Green test and the Batalla test.
Results: Ninety-six patients were included, mostly women (59%), white (76%), and 
with mean age of 52 ± 12 years. Only 49% of patients adhered to drug treatment 
according to the Batalla test, while 24% were classifed as high adherence, 41% as 
moderate adherence and 34% as low adherence to drug treatment according to the 
modifed Morisky Green test. Considering glycated hemoglobin levels as a reference 
method, only 37% of patients were within the currently recommended values, with 
higher adherence among women compared to men (44% vs. 23%, P = 0.044).
Conclusions: The prevalence of adherence among patients with T2D was very low. 
Older age, insulin therapy and male sex were more strongly associated with worse 
adherence. The main barrier limiting treatment adherence was lack of motivation, 
especially due to difculties in adopting a healthy and balanced diet.
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Type 2 diabetes (T2D) comprises 90 to 95% of patients with diabetes, 
thus representing the most common form of the disease1. Its relevance in the 
current medical setting is justified by its increasing prevalence and significant 
morbidity and mortality. It is characterized by deficient insulin action and/or 
secretion, resulting in hyperglycemia and predisposition to develop multiple 
micro- and macrovascular complications2. Obesity, defined as body mass 
index (BMI) higher than or equal to 30 kg/m2, is found in most patients with this 
form of diabetes, in addition to concomitant diseases, such as dyslipidemia 
and systemic arterial hypertension (SAH)1.
T2D treatment consists of lifestyle changes – a balanced diet, rich in 
complex carbohydrates and unsaturated fats, and physical exercise, in addition 
to oral hypoglycemic agents associated or not with insulin3. Despite the 
importance of glucose control, nonadherence to drug and non-drug treatment 
is quite frequent in this population, which increases the risk of complications 
and mortality. It is estimated that 50% of patients with chronic diseases in 
developed countries are nonadherent to drug therapies, and this rate is even 
higher in developing countries such as Brazil4.
Adherence to treatment is usually multifactorial, involving factors related 
to patient, healthcare provider and healthcare system5,6. Thus, several 
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methods have been developed over recent decades 
to assess adherence to drug therapy. However, so 
far, there is no method that could be considered 
the “gold standard” to assess behavior related to 
adherence to drug therapy7,8.
The Morisky-Green test (MGT) is a validated 
questionnaire that assesses patient’s attitude toward 
treatment9,10. Despite having been initially created 
to assess adherence within the scope of SAH, this 
test has been used for assessing several chronic 
diseases, including diabetes9. Another common 
instrument is the Batalla test, which evaluates patient’s 
level of knowledge of the disease11. In addition to 
indirect methods, regular monitoring of glycated 
hemoglobin (Hb1Ac) levels is another measure for 
adherence in DM.
Considering the prevalence of T2D as well as 
the socioeconomic impact of chronic complications 
associated with poor disease control, the purpose 
of this study was to evaluate the sociodemographic 
profile of patients with T2D, identifying the prevalence 
of adherence to pharmacological treatment as well 
as the major obstacles to handling such patients.
METHODS
Design
This cross-sectional study was conducted at an 
endocrinology outpatient clinic and at an inpatient ward 
of the University Hospital of Canoas, metropolitan 
area of Porto Alegre, southern Brazil. Patients were 
interviewed between March 2016 and March 2017.
Patients
Patients of both sexes, older than 18 years of age, 
diagnosed with T2D for at least 6 months, regularly 
followed at the endocrinology outpatient clinic or 
admitted to the hospital, were consecutively included.
Patients who refused to sign an informed consent 
form and patients diagnosed with other types of 
diabetes were excluded. This study was approved 
by the Ethics Committee at the University Hospital 
of Canoas and informed consent was obtained from 
all participants.
Clinical and Anthropometric Measurements
A standard questionnaire concerning sociodemographic 
and clinical aspects, including comorbidities, drugs 
being used and method to obtain the drugs, was 
administered. In addition, a brief physical examination 
was performed to assess anthropometric measures 
and blood pressure.
Weight (kg) and height (cm) were measured with 
patients wearing lightweight clothes and no shoes 
while standing on scales with capacity for 300 kg 
(Welmy). BMI was calculated by dividing weight by 
squared height (kg/m2). Patients were classified as 
eutrophic (BMI ranging from 18.5 to 24.9 kg/m2), 
overweight (BMI ranging from 25 to 29.9 kg/m2) or 
obese (BMI ≥ 30 kg/m2), according to World Health 
Organization criteria12. Abdominal circumference (cm) 
was measured at the mid-point between the last rib 
and the iliac crest with a fiberglass tape measure13.
To assess blood pressure, two measures were 
taken, at 2-minute intervals, using a cuff suitable 
to arm diameter, by the oscillometric method. 
A patient was deemed hypertensive if mean systolic 
blood pressure (SBP) was greater than or equal to 
140 mmHg and/or diastolic blood pressure (DBP) 
was greater than or equal to 90 mmHg on at least 
2 occasions, or if the patient had had a prior event 
of SAH during pharmacological treatment regardless 
of blood pressure levels14.
Biochemical Parameters
Fasting glucose levels were determined by 
glucose-oxidase method; creatinine by Jaffe reaction; 
Hb1Ac by high-performance liquid chromatography 
(HPLC; Merck-Hitachi 9100; reference range: 4-6%); 
triglycerides and cholesterol by enzymatic method; 
and low-density lipoprotein (LDL) cholesterol by 
Friedewald equation. The Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) formula15 was 
used to estimate glomerular filtration rate.
Assessment of Adherence
Adherence was assessed only once and individually, 
prior to medical evaluation, by administering the 
modified MGT and the Batalla test. In the modified 
MGT, individuals answered yes or no to six questions. 
The first four questions were:
1. “Do you ever forget to take your medicine?” 
(0) yes1, no;
2. “Are you careless at times about taking your 
medicine?” (0) yes1, no;
3. “When you feel better do you sometimes stop 
taking your medicine?” (0) yes1, no;
4. “Sometimes if you feel worse when you take your 
medicine, do you stop taking it?” (0) yes1, no.
Individuals answering any of these four questions 
affirmatively were submitted to two additional questions:
5. “Were you informed of the importance and benefit 
of using your medicine?”
6. “Do you forget to get more medicines before they 
run out?”
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High adherence was defined as score equal to 
4 points; moderate adherence as score equal to 2 
or 3 points; and low adherence as score equal to 1 
or 0 point. Individuals answering yes to questions 1 
and/or 2 were characterized as having behavior of 
unintentional nonadherence, and individuals who 
answered yes to questions 3 and/or 4, as having 
intentional nonadherence9. Individuals answering 
no to question 5 were considered as not realizing 
the importance of treatment; an affirmative answer 
to question 6 suggested lack of motivation as the 
reason for nonadherence.
In the Batalla test, treatment adherence was 
assessed by asking three questions about familiarity 
with the disease: 1) “Is T2D a lifelong disease?”; 
2) “Can T2D be controlled with diet and/or drugs?”; 
3) “Mention 2 or more organs affected by T2D.” 
A wrong answer rated the patient as nonadherent11.
Adherence was assessed by considering all drugs 
prescribed for the patient, including those prescribed 
for treatment of concurrent diseases. Performance in 
both questionnaires was compared to Hb1Ac levels, 
a more objective measure to monitor response to 
treatment.
Statistical Analysis
To calculate the sample size, it was estimated that 
for a 40% prevalence of nonadherence, considering 
P <0.05 as statistically significant and a 90% power, 
92 patients were necessary. Quantitative variables 
were expressed as mean ± standard deviation (SD) 
or median and interquartile range, with normal and 
non-normal distribution, respectively. Patients were 
divided into two groups to analyze the results: adherent 
and nonadherent to drug treatment. Those who 
scored 4 points in the modified MGT were classified 
as adherent and those who scored 3 points or less, 
or those who gave one wrong answer in the Batalla 
test were classified as nonadherent. The Student’s 
t-test for independent samples or the chi-square 
test was used to evaluate the association between 
variables and nonadherence.
A logistic regression analysis was performed 
to assess the predictive independent variables of 
adherence to pharmacological treatment, using the 
Batalla test or the MGT as a dependent variable, 
and age, sex, level of education, income, duration of 
T2D and insulin therapy as independent variables. 
The analyses were performed using the Statistical 
Package for the Social Science software (SPSS, 
version 20.0 for Windows) and P <0.05 was considered 
significant.
To analyze the performance of the Batalla and 
MGT questionnaires, descriptive sensitivity and 
specificity were measured.
RESULTS
Sociodemographic Profile and Laboratory 
Characteristics of Patients with T2D
Ninety-six patients were assessed. Their mean age 
was 52 ± 12 years. Most of them were women (59%, 
n = 57) and Caucasians (76%, n = 73). Their mean 
BMI was 27 ± 6 kg/m2. Clinical and laboratory 
characteristics of the patients with T2D according 
to sex are described in Table 1. Approximately 73% 
(n = 67) of the patients were in a stable relationship. 
With respect to tobacco use, about 46% of the 
patients were current or former smokers. Most of 
the patients were unemployed (71%). Their mean 
level of education was 6.4 ± 3.2 years of formal 
instruction, and their mean per capita income was 
1,135.5 ± 595.3 reais (Brazilian currency). The mean 
use of daily medications was 5.9 ± 2.5 per patient 
– 71% (n = 69) took five or more medications a 
day while 8% (n = 8) took 10 or more medications 
a day, and 51% (n = 47) got medications only from 
drugstores at their Primary Health Care Units. Most 
patients had SAH (87%, n = 80) and were under 
pharmacological treatment, and 36% had abnormal 
blood pressure at the time of the interview.
The mean duration of T2D was 11.5 ± 6.5 years. 
With regard to disease complications, a little more 
than half the patients (52%) had microvascular 
complications: 21% had diabetic retinopathy, 32% had 
diabetic neuropathy, 14% had diabetic nephropathy 
and 22% had more than one of these. With regard to 
macrovascular complications, 16% patients reported 
prior myocardial infarction and 7.6% reported prior 
cerebrovascular accident.
Regarding pharmacological treatment, 52% of 
patients were receiving oral therapy for T2D, 40.6% 
were under combined treatment (oral therapy + insulin 
therapy) and 7.2% were receiving only insulin therapy. 
Regarding laboratory tests, mean fasting glucose 
was 172.4 ± 74.5 mg/dL and Hb1Ac was 7.9 ± 1.9%. 
Regarding lipid profile, 21% of the patients had total 
cholesterol levels above the desired value, 28% had 
triglyceride levels above 150 mg/dL and 55% had 
HDL levels lower than the expected.
Assessment of Degree of Adherence to 
Pharmacological Treatment
Batalla test
Assessment of adherence according to clinical and 
laboratory variables is shown in Table 2. With regard 
to assessment of adherence by the Batalla test, only 
49% of the patients adhered to the treatment, with 
no difference between sexes (P = 0.279). Older age 
was associated with greater risk of nonadherence 
(P = 0.017). Treatment with insulin showed a tendency 
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to worse adherence (P = 0.052). With regard to 
laboratory variables, patients with higher adherence 
had both higher fasting glucose and higher Hb1Ac 
levels (P = 0.037 and 0.003, respectively) than those 
with lower adherence.
Among all patients, 51% (n = 47) were not able 
to mention at least two organs affected by T2D. 
A logistic regression analysis was conducted to 
assess predictive independent variables of adherence 
to pharmacological treatment, using the Batalla 
test as a dependent variable. The overall success 
rate (accuracy) of the test was 69.6%, with 77.8% 
specificity and 57.9% sensitivity. Of all variables 
tested in the model (age, sex, level of education, 
income, duration of T2D and insulin therapy), only 
insulin therapy was associated with worse adherence 
(β = -0.422, P = 0.044).
Morisky-Green Test (MGT)
Concerning assessment of adherence by the MGT, 
24% (n = 23) of the patients were classified as high 
adherence, 41% (n = 40) as mean adherence and 
34% (n = 33) as low adherence. Table 3 shows the 
percentage of negative answers (higher adherence) 
for each question of the test.
Among the patients classified as nonadherent 
(mean or low adherence), 70% were classified 
as unintentional, 37% as intentional and 33% as 
both, as described in Table 4. Furthermore, lack 
of motivation was found to be more prevalent as 
a cause of nonadherence than lack of familiarity 
with importance of treatment, with 57% and 28%, 
respectively.
Assessment of adherence by the MGT is shown 
in Table 5. All clinical and laboratory variables were 
similar among patients with and without adherence, 
Table 1: Clinical and laboratory characteristics of patients with T2D.
Clinical variables Female Male P
Age (years) 64 ± 13 64 ± 9 0.852
Caucasians – n (%) 45 (79%) 27 (73%)
Income (reais)* – n (%) 0.359
<1 16 (28%) 10 (25%)
1 to 3 40 (70%) 26 (67%)
3 to 5 1 (2%) 3 (8%)
Education (years) 0.553
0 4 (7%) 1 (2,5%)
1 to 4 11 (19%) 9 (23%)
5 to 9 36 (63%) 23 (59%)
10 or more 6 (10%) 6 (15%)
Smoker (%) 0.019
Current 2 (3.5%) 2 (5.1%)
Previous 18 (31.6%) 23 (58.9%)
Never smoked 37 (64.9%) 14 (35.8%)
Body mass index (kg/m2) 30.6 ± 6.9 28.4 ± 5.7 0.103
Waist circumference (cm) 101.3 ± 12.4 97.5 ± 18.2 0.376
T2D duration (years) 11.6 ± 7.9 11.4 ± 9.5 0.940
Insulin therapy – n (%) 29 (51%) 21 (54%) 0.469
SBP (mmHg) 130.4 ± 16.7 134.3 ± 13.9 0.229
DBP (mmHg) 82.8 ± 10.1 85.0 ± 8.8 0.295
Laboratory variables
Fasting glucose (mg/dL) 159.8 ± 62.2 190.5 ± 87.0 0.140
Hb1Ac (%) 7.5 ± 1.7 8.5 ± 2,0 0.025
Total cholesterol (mg/dL) 183.0 ± 63.7 160.9 ± 42.3 0.115
HDL (mg/dL) 38.2 ± 15.9 36.1 ± 8.7 0.510
Triglycerides (mg/dL) 180.0 (42-598) 136.0 (47-262) 0.037
LDL (mg/dL) 106.2 ± 51.2 97.2 ± 37.6 0.456
Creatinine (mg/dL) 1.1 ± 0.7 1.3 ± 1.1 0.349
GFR – CKD-EPI (mL/min/1.73 m2) 65.3 ± 28.8 73.4 ± 28.7 0.213
SBP, systolic blood pressure; DBP, diastolic blood pressure; Hb1Ac, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; GFR – CKD-EPI, glomerular filtration rate – Chronic Kidney Disease Epidemiology Collaboration; *Income according to minimum 
wage in Brazil; T2D – type 2 diabetes.
http://seer.ufrgs.br/hcpaClin Biomed Res 2018;38(4)328
Vicenzi, Moehlecke
except for lower total cholesterol levels in patients 
with higher adherence (P = 0.036).
Most patients (67%) answered that their main difficulty 
during treatment is adopting a diet. Approximately 
one third (n = 25) of the patients answered physical 
exercise as the main challenge, 6% answered insulin 
application and another 6% answered that they do 
not take the prescribed drugs, either because they 
forget or because of the large number of drugs they 
should take.
The overall success rate (accuracy) of the test was 
71.7%, with 14.3% specificity and 96.7% sensitivity. 
No variable tested in the logistic regression model 
(age, sex, level of education, income, duration of T2D 
and insulin therapy) predicted worse adherence to 
pharmacological treatment.
Glycated hemoglobin (Hb1Ac) as a reference 
method
Considering Hb1Ac levels lower than or equal to 
7% as optimal for glucose control, only 37% (n = 31) of 
the patients were within the current recommendation, 
with predominance of women compared to men 
Table 2: Clinical and laboratory variables associated with adherence to treatment in patients with T2D according to the 
Batalla Test.
Batalla Test Adherence Nonadherence P*
Clinical variables
Sex 0.279
Female 26 (45%) 31 (55%)
Male 21 (54%) 18 (46%)
Age (years) 61.1 ± 10.5 66.6 ± 11.9 0.017
Income (reais) 1210 ± 660 1064 ± 522 0.233
Years of education 6.7 ± 2.9 6.1 ± 3.5 0.452
T2D (years) 13.1 ± 9.3 10.0 ± 7.5 0.071
Insulin therapy – n (%) 20 (40%) 30 (60%) 0.052
Body mass index (kg/m2) 30.0 ± 5.5 29.5 ± 7.5 0.720
SBP (mmHg) 133 ± 14 131 ± 17 0.477
DBP (mmHg) 85 ± 8 82 ± 10 0.118
Laboratory variables
Fasting glucose (mg/dL) 159 ± 54 148 ± 48 0.037
Hb1Ac (%) 8.6 ± 2.0 7.3 ± 1.5 0.003
TC (mg/dL) 178 ± 48 170 ± 67 0.609
HDL (mg/dL) 35 ± 12 39 ± 14 0.239
Triglycerides (mg/dL) 160 (47-598) 135 (42-400) 0.096
LDL (mg/dL) 103 ± 39 100 ± 52 0.768
Creatinine (mg/dL) 1.1 ± 0.9 1.3 ± 0.9 0.672
GFR – CKD-EPI (mL/min/1.73 m2) 72.5 ± 26.0 65.4 ± 30.9 0.268
SBP, systolic blood pressure; DBP, diastolic blood pressure; Hb1Ac, glycated hemoglobin; TC, total cholesterol; HDL, high-density lipoprotein; 
LDL, low-density lipoprotein; GFR – CKD-EPI, glomerular filtration rate – Chronic Kidney Disease Epidemiology Collaboration; *P <0.05 was 
considered significant; Data are presented as mean ± SD or median (interquartile range); T2D – type 2 diabetes.
Table 3: Assessment of adherence to pharmacological treatment according to the Morisky-Green test.
Questions n (%)*
Do you ever forget to take your medicine?” 35 (36%)
Are you careless at times about taking your medicine? 35 (36%)
When you feel better do you sometimes stop taking your medicine? 63 (65%)
Sometimes if you feel worse when you take your medicine, do you stop taking it? 65 (67.7%)
*Negative answers mean greater compliance.







Lack of knowledge 27 (28%)
Lack of motivation 55 (57%)
Lack of knowledge and motivation 26 (27%)
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(44% vs. 23%, respectively; P = 0.044). The remaining 
clinical and laboratory variables tested were not 
associated with better glucose control.
DISCUSSION
Based on the results found in this study, we are 
able to conclude that most patients with T2D treated 
at our hospital were overweight, women, Caucasians, 
with low level of education and monthly income a 
little higher than one minimum wage. Additionally, 
most of them had chronic complications of T2D and 
were taking multiple drugs on a daily basis, with 
complex therapeutic regimens, which encourages 
pharmacological nonadherence. In addition, most of 
the patients had fasting glucose and Hb1Ac values 
above the desired levels.
According to the results of the Batalla test, less 
than half the patients showed adherence to drug 
treatment. Insulin therapy was associated with poor 
adherence to pharmacological treatment, similar to 
findings described in previous studies16,17. Nam et al., 
in their review of barriers to DM treatment, showed 
that patients who need insulin therapy tend to find 
adherence to treatment more difficult17.
According to the results of the MGT, in turn, only 
approximately one fifth of the patients adhered to 
the drug treatment proposed. A cross-sectional 
Brazilian study assessing treatment adherence in 
54 diabetic patients found that, according to the 
answers to the MGT questions, only 33% of the 
patients were considered adherent to therapy, a 
similar result to that found in our study18. Also, the 
MGT questionnaire seems to be more reliable when 
a patient reports not taking the drugs, i.e., it shows a 
high negative predictive value. Similar results were 
described by Silvestre-Busto et al. in a cross-sectional 
study performed in Spain including 2,244 patients. 
It showed that those who reported being nonadherent 
in the MGT were telling the truth19.
Comparing the two tests, we observed that the 
MGT seems more sensitive to detect nonadherent 
patients and is more accurate than the Batalla test. 
Thus, we believe that MGT is a better option to measure 
treatment adherence.
In general, we found a low prevalence of adherence 
to drug treatment in patients with T2D, when Hb1Ac was 
used as a reference method. Female sex was associated 
with a higher probability of adherence. This  was also 
described by Gorter et al. in a cross-sectional study 
of 1,029 patients who were asked about their goals 
and responsibilities regarding DM. The results showed 
greater concern with health among women compared 
to men, as women showed more interest and sought 
Table 5: Clinical and laboratory variables associated with adherence to pharmacological treatment in patients with T2D 




Female 15 (26%) 42 (74%)
Male 8 (20%) 31 (80%)
Age (years) 65.7 ± 11.8 63.3 ± 11.5 0.389
Income (reais) 1066 ± 386 1157 ± 648 0.524
T2D duration (years) 13.8 ± 9.8 10.8 ± 8.0 0.135
Insulin therapy – n (%) 9 (18%) 41 (82%) 0.118
Body mass index (kg/m2) 29.4 ± 5.0 29.8 ± 7.0 0.767
SBP (mmHg) 133 ± 14 132 ± 16 0.838
DBP (mmHg) 82 ± 8 84 ± 9 0.517
Laboratory variables
Fasting glucose (mg/dL) 144 ± 46 156 ± 52 0.399
Hb1Ac (%) 7.7 ± 1.8 7.9 ± 1.8 0.618
TC (mg/dL) 145 ± 46 182 ± 56 0.036
HDL (mg/dL) 33 ± 15 38 ± 12 0.234
Triglycerides (mg/dL) 138 (42-485) 140 (47-598) 0.894
LDL (mg/dL) 83 ± 36 107 ± 47 0.088
Creatinine (mg/dL) 1.2 ± 0.9 1.2 ± 0.9 0.976
GFR – CKD-EPI 69.9 ± 33.3 65.6 ± 31.2 0.753
SBP, systolic blood pressure; DBP, diastolic blood pressure; Hb1Ac, glycated hemoglobin; TC, total cholesterol; HDL, high-density lipoprotein; 
LDL, low-density lipoprotein; GFR – CKD-EPI, glomerular filtration rate – Chronic Kidney Disease Epidemiology Collaboration; *P < 0.05 was 
considered significant.
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more care20. We also noted that, despite evidence 
of the importance of doing exercise and adopting a 
healthy diet, most patients still find it difficult to carry 
out such activities, as two thirds claimed that diet was 
the main obstacle for treatment, while almost one third 
said that it was physical exercise.
Our study has some limitations that should be 
considered when interpreting the main results. This is 
a cross-sectional study, a design that does not allow 
inferring causality. Additionally, the performance of 
the Batalla test may have been compromised in 
inpatients due to T2D complications, as nonadherent 
patients showed better glucose control than adherent 
patients. The reason is that many of those who were 
able to mention at least two organs compromised by 
diabetes had an acute complication (memory bias).
CONCLUSION
The results obtained in this study allow us 
to conclude that there is very low adherence to 
pharmacological treatment among patients with T2D. 
Male sex, using Hb1Ac levels as a direct method to 
evaluate glucose control and older age, considering 
the Batalla test, were more strongly associated with 
worse adherence. In addition, insulin therapy as 
evaluated by the Batalla test showed a tendency 
to worse adherence . The main barrier limiting 
the treatment of nonadherent patients was lack of 
motivation, especially due to difficulties in adopting 
a healthy and balanced diet. Regarding the use of 
indirect methods to assess adherence, the MGT 
showed higher sensitivity and negative predictive 
value compared to the Batalla test, thus being a 
better option to measure treatment adherence.
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